JAK1-IN-31

CAS No. 1315498-72-6

JAK1-IN-31( —— )

Catalog No. M11278 CAS No. 1315498-72-6

JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JAK1-IN-31
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM.
  • Description
    JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM); exhibits favorable oral bioavailability across a range of preclinical species and robust efficacy in a rat CIA model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1315498-72-6
  • Formula Weight
    449.529
  • Molecular Formula
    C23H23N5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    trans-4-(2-((R)-1-Hydroxyethyl)-6-(phenylsulfonyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexanecarbonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zak M, et al. J Med Chem. 2013 Jun 13;56(11):4764-85.
molnova catalog
related products
  • PF-06700841 (P-Tosyl...

    PF-06700841 P-Tosylate is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).

  • PF-06651600

    PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical

  • FM-381

    FM-381 (FM381) is a potent, specific, reversible and covalent inhibitor of JAK3 with IC50 of 127 pM.